Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant

Next Previous
Trial Profile

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Ezetimibe/simvastatin; Simvastatin
  • Indications Cardiovascular disorders; Dyslipidaemias; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms HPS2-THRIVE

    • Most Recent Events

    • 22 Aug 2019 Results exploring the safety profile of niacin-laropiprant and examining whether any patients were at lower (or higher) risk of its adverse effects published in the Clinical Therapeutics
    • 25 Mar 2013 Adverse events of this trial are reported to be consistent with those in the AIM-HIGH trial (niacin extended-release monotherapy), according to the University of Oxford media release.
    • 11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology. Additional information taken from slides presented at the conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top